1-(2-氟乙基)-2-甲基-5-硝基咪唑

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-氟乙基)-2-甲基-5-硝基咪唑
• 中文别名: 4-氨基-5-溴-N-[2-(二乙基氨基)乙基]-2-甲氧基苯甲酰胺单盐酸盐；盐酸溴溴化物
• 英文名称: 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide;hydron;chloride
• 化学式: C14H23BrClN3O2
• 分子量: 380.71
• InChiKey: SGQFXUUDHWNAIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.53
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
  申请人：Chase Pharmaceuticals Corporation

  公开号：US10307409B2

  公开（公告）日：2019-06-04

  A combination of a muscarinic cholinergic receptor agonist, a non-anticholinergic antiemetic agent and a non-selective, peripheral anticholinergic agent for the treatment of hypocholinergic disorders of the central nervous system.

  一种毒蕈碱胆碱能受体激动剂、一种非抗胆碱能止吐药和一种非选择性外周抗胆碱能药的复方制剂，用于治疗中枢神经系统的低胆碱能紊乱。
• Memantine combinations and use
  申请人：CHASE PHARMACEUTICALS CORPORATION

  公开号：US10548855B2

  公开（公告）日：2020-02-04

  A pharmaceutical combination of memantine and a non-anticholinergic antiemetic agent for the treatment of hypocholinergic disorders in further combination with high doses of donepezil and with solifenacin, and kits comprising said combination. A pharmaceutical combination of memantine and solifenacin for the treatment of hypocholinergic disorders, including Alzheimer type dementia, in further combination with high doses of donepezil, and kits comprising said combination.

  一种治疗低胆碱能紊乱的美金刚和非抗胆碱能止吐药的药物组合，进一步与大剂量多奈哌齐和索利芬那新组合，以及包含所述组合的试剂盒。一种美金刚和索利芬那新的药物组合，用于治疗低胆碱能疾病，包括阿尔茨海默型痴呆，进一步与大剂量多奈哌齐组合，以及包含所述组合的试剂盒。
• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。
• PHARMAZEUTISCHE DARREICHUNGSFORM
  申请人：Müller, Dieter

  公开号：EP0907388A1

  公开（公告）日：1999-04-14
• DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
  申请人：The Scripps Research Institute

  公开号：EP2675893A1

  公开（公告）日：2013-12-25